Protocol Ledger

NCT04620239 · Phase III · ACTIVE NOT RECRUITING

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Interventional Phase III clinical trial protocol NCT04620239 sponsored by Steba Biotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-22 Enrollment: 89 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04620239
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)89 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04620239
Protocol FieldVerified Registry Value
NCT IdentifierNCT04620239
Consolidated Lead SponsorSteba Biotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment89 participants (ACTUAL)
Registered Start Date2021-03-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI